Earnings Call Summary | Henry Schein(HSIC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Henry Schein(HSIC.US) Q1 2024 Earnings Conference
The following is a summary of the Henry Schein, Inc. (HSIC) Q1 2024 Earnings Call Transcript:
以下是亨利·舍因公司（HSIC）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Henry Schein reported Q1 global sales of $3.2 billion, up by 3.7%.
Q1 GAAP net income was $93 million or $0.72 per diluted share, a decrease from the prior year's GAAP net income.
Non-GAAP net income for Q1 was $143 million or $1.10 per diluted share, lower than the prior year's figure.
The company expects non-GAAP diluted EPS for 2024 to be in the range of $5 to $5.16 per share, up by 11% to 15% from the 2023 figure of $4.50.
Sales decrease was primarily due to lower glove prices but the reduced impact on sales growth from PPE is anticipated throughout the year.
亨利·舍因報告稱，第一季度全球銷售額爲32億美元，增長3.7％。
第一季度GAAP淨收益爲9,300萬美元，攤薄每股收益爲0.72美元，低於上一年的GAAP淨收益。
第一季度的非公認會計准則淨收益爲1.43億美元，攤薄後每股收益爲1.10美元，低於上一年的數字。
該公司預計，2024年的非公認會計准則攤薄每股收益將在5美元至5.16美元之間，較2023年的4.50美元增長11％至15％。
銷售額下降主要是由於手套價格下跌，但預計全年個人防護裝備對銷售增長的影響將減弱。
Business Progress:
業務進展：
Significant recovery from a prior cyber incident.
The company's THRIVE Signature program saw about 2,000 new members in Q1.
Increased growth in dental specialties across oral surgical products, endodontics, and orthodontics due to acquisitions.
Henry Schein One saw a 36% increase in its customer base for cloud-based solutions.
Henry Schein completed the acquisition of TriMed.
The company is well-positioned to expand in the competitive implant market with planned product launches.
Stable margins were maintained in their dental businesses despite some pricing pressures.
The company is accelerating normal operations post-cybersecurity incident with new software products.
CEO Stanley Bergman sees a stable and growth-oriented global dental market.
從先前的網絡事件中恢復過來。
該公司的THRIVE Signature計劃在第一季度吸引了約2,000名新會員。
由於收購，口腔外科產品、牙髓治療和正畸領域的牙科專業增長加快。
Henry Schein One的基於雲的解決方案的客戶群增長了36％。
Henry Schein 完成了對 TriMed 的收購。
通過計劃推出產品，該公司完全有能力在競爭激烈的植入物市場中擴張。
儘管存在一些定價壓力，但他們的牙科業務仍保持了穩定的利潤率。
該公司正在通過新的軟件產品加快網絡安全事件後的正常運營。
首席執行官斯坦利·伯格曼認爲，全球牙科市場將保持穩定且以增長爲導向。
More details: Henry Schein IR
更多詳情： 亨利·舍因 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。